News
CAR T Cells: Off the Shelf and On the Mark
After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with some concrete limitations.
Exacis Biotherapeutics Announces Key Additions To Company’s Scientific Advisory Board
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of three oncology and cell therapy experts to its Scientific Advisory Board (SAB): Pamela Munster, MD; Caron Jacobson, MD, MMSc; and Evren Alici, MD, PhD.
Exacis Biotherapeutics Makes Strategic Investment In Manufacturing By Hiring Head Of Technical Operations and Securing Space In A GMP Cleanroom Facility Recently Completed By Factor Bioscience
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer
Exacis Biotherapeutics Presents Data On Its Stealth mRNA-engineered NK-cell Platform At American Society Of Gene & Cell Therapy Annual Meeting
Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies
Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells For Difficult-To-Treat Tumors
Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.
Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of Dirk Huebner, MD, as its Chief Medical Officer.